P-glycoprotein antibody-conjugated paclitaxel liposomes targeted for multidrug-resistant lung cancer

To overcome the resistance of lung cancer to paclitaxel. P-glycoprotein antibody-conjugated paclitaxel PEG-coated immunoliposomes (Pab-PTX-L) were prepared, and a series of quality evaluations, cell evaluation and assessment of their antitumor effect in mice were conducted. The results showed that P...

Full description

Saved in:
Bibliographic Details
Published in:Nanomedicine (London, England) England), 2023-04, Vol.18 (10), p.819-831
Main Authors: Wang, Jianfei, Suo, Xubin, Zhang, Han
Format: Article
Language:English
Subjects:
Animals
Apoptosis
ATP Binding Cassette Transporter, Subfamily B, Member 1
Cell Line, Tumor
Drug Delivery Systems - methods
Drug Resistance, Neoplasm
liposomes
Liposomes - therapeutic use
lung cancer
Lung Neoplasms - drug therapy
Lung Neoplasms - pathology
Mice
multidrug resistance
P-glycoprotein antibody conjugated
paclitaxel
Paclitaxel - pharmacology
Paclitaxel - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To overcome the resistance of lung cancer to paclitaxel. P-glycoprotein antibody-conjugated paclitaxel PEG-coated immunoliposomes (Pab-PTX-L) were prepared, and a series of quality evaluations, cell evaluation and assessment of their antitumor effect in mice were conducted. The results showed that Pab-PTX-L was nano-sized with high encapsulation efficiency of paclitaxel. For the paclitaxel-resistant lung cancer A549/T cells, the cellular uptake and cell viability inhibition and apoptosis of Pab-PTX-L-treated cells were higher than those of the control groups. More importantly, Pab-PTX-L showed a good targeting and antitumor effect on tumor tissue in mouse experiments. This study will provide a new insight on enhanced paclitaxel delivery into paclitaxel-resistant cancer cells.
ISSN:1743-5889
1748-6963
DOI:10.2217/nnm-2023-0015